ABUS - Arbutus Biopharma Corp

QQQ $ 482.14 $ -2.03 (-0.42 %)

DIA $ 408.56 $ -1.88 (-0.46 %)

SPY $ 560.69 $ -1.72 (-0.31 %)

TLT $ 97.81 $ -0.40 (-0.41 %)

GLD $ 229.26 $ -1.01 (-0.44 %)

Previous Close

$ 3.87

Open

$ 3.91

Bid

$ 3.85 x 600

Ask

$ 3.86 x 300

Day's Range

$ 3.86 - $ 3.91

52 Week Range

$ 1.69 - $ 3.98

Volume

1,065,692

Average Volume

Market Cap

730.59M

Beta (5Y Monthly)

$ 1.03

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-08-2024	06-30-2024	10-Q
2	05-02-2024	03-31-2024	10-Q
3	03-05-2024	12-31-2023	10-K
4	11-07-2023	09-30-2023	10-Q
5	08-03-2023	06-30-2023	10-Q
6	05-04-2023	03-31-2023	10-Q
7	03-02-2023	12-31-2022	10-K
8	11-09-2022	09-30-2022	10-Q
9	08-04-2022	06-30-2022	10-Q
10	05-05-2022	03-31-2022	10-Q
11	03-03-2022	12-31-2021	10-K
12	11-04-2021	09-30-2021	10-Q
13	08-05-2021	06-30-2021	10-Q
14	05-05-2021	03-31-2021	10-Q
15	03-04-2021	12-31-2020	10-K
16	11-05-2020	09-30-2020	10-Q
17	08-07-2020	06-30-2020	10-Q
18	05-11-2020	03-31-2020	10-Q
19	03-05-2020	12-31-2019	10-K
20	11-06-2019	09-30-2019	10-Q
21	08-05-2019	06-30-2019	10-Q
22	05-06-2019	03-31-2019	10-Q
23	03-07-2019	12-31-2018	10-K
24	11-07-2018	09-30-2018	10-Q
25	08-03-2018	06-30-2018	10-Q
26	05-04-2018	03-31-2018	10-Q
27	03-16-2018	12-31-2017	10-K
28	11-02-2017	09-30-2017	10-Q
29	08-03-2017	06-30-2017	10-Q
30	05-04-2017	03-31-2017	10-Q
31	03-22-2017	12-31-2016	10-K
32	11-03-2016	09-30-2016	10-Q
33	08-04-2016	06-30-2016	10-Q
34	05-04-2016	03-31-2016	10-Q
35	03-09-2016	12-31-2015	10-K
36	11-05-2015	09-30-2015	10-Q
37	08-07-2015	06-30-2015	10-Q
38	05-06-2015	03-31-2015	10-Q
39	03-13-2015	12-31-2014	10-K
40	11-07-2014	09-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

JMP Securities Maintains Market Outperform...
08/02/2024 17:55:14

JMP Securities analyst Roy Buchanan maintains Arbutus Biopharma (NASDAQ:ABUS) with a Market Outperform and raises the price ...

Trading Halt: Halt status updated at 7:55:...
08/01/2024 11:55:07

Arbutus Will Cease Discovery Efforts And D...
08/01/2024 11:35:24

With These Organizational Changes And Its Ongoing Cost Management Efforts, The Company Now Expects Its Current Cash, Cash Equiv...

Arbutus Biopharma Q2 2024 GAAP EPS $(0.11)...
08/01/2024 11:32:13

Trading Halt: Halted at 7:25:00 a.m. ET - ...
08/01/2024 11:25:04

HC Wainwright & Co. Reiterates Buy on Arbu...
06/07/2024 15:29:53

HC Wainwright & Co. analyst Ed Arce reiterates Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $5 price target.

Barinthus Biotherapeutics Presents Updated...
06/06/2024 15:16:01

In the HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed fo...

HC Wainwright & Co. Reiterates Buy on Arbu...
06/06/2024 10:36:49

HC Wainwright & Co. analyst Ed Arce reiterates Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $5 price target.

Chardan Capital Maintains Buy on Arbutus B...
06/05/2024 20:20:24

Chardan Capital analyst Keay Nakae maintains Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $4 price target.

Arbutus's Imdusiran Combined With Short-Te...
06/05/2024 07:50:33

At the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleo...

Arbutus Biopharma Announces Presentation O...
05/22/2024 06:29:12

Key Findings: HBsAg ≤ LLOQ (lower limit of quantification) with detectable anti-HBs was observed at end-of-treatment in 28% of ...

Genevant Sciences And Arbutus Biopharma Wi...
05/20/2024 16:52:06

https://storage.courtlistener.com/recap/gov.uscourts.njd.515917/gov.uscourts.njd.515917.35.0.pdf

Chardan Capital Reiterates Buy on Arbutus ...
05/03/2024 13:21:22

Chardan Capital analyst Keay Nakae reiterates Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $4 price target.

Arbutus Biopharma Q1 EPS $(0.10) Beats $(0...
05/02/2024 11:31:35

Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0...

arbutus-vs-moderna-patent-dispute-over-covid-19-vaccine-gets-response-from-judge

Arbutus Vs. Moderna Patent Dispute Over Co...
04/04/2024 18:32:00

Delaware Judge favors Arbutus and Genevant Sciences in their patent dispute with Moderna over COVID-19 vaccine technology.

moderna-shares-slip-over-covid-vaccine-patent-dispute-but-chart-signals-potential-rebound-ahead

Moderna Shares Slip Over Covid Vaccine Pat...
04/04/2024 13:34:25

Moderna stock falls 2.32% due to patent infringement suit. However, some investors see this as an opportunity to enter or avera...

JMP Securities Reiterates Market Outperfor...
04/04/2024 12:49:09

JMP Securities analyst Roy Buchanan reiterates Arbutus Biopharma (NASDAQ:ABUS) with a Market Outperform and maintains $4 pri...

Arbutus Biopharma Announces Claim Construc...
04/04/2024 12:42:17

The following summarizes the Court's Opinion:Composition of Total Lipid (‘069)The Court agreed with Plaintiffs' positio...

arbutus-stock-soars-20-as-it-heads-to-trial-with-moderna-in-covid-vaccine-patent-claim

Arbutus Stock Soars 20% As It Heads To Tri...
04/03/2024 19:37:15

Arbutus Biopharma soared more than 20% on Wednesday, April 3, after the company received permission to pursue a claim against M...

Watching Arbutus Biopharma; Traders Circul...
04/03/2024 16:22:12

Arbutus and Genevant vs Moderna Claim Construction Order.pdf | DocDroid